Veterinary Medicines

EFFIPRO 268 MG SPOT-ON SOLUTION FOR LARGE DOGS

Authorised
  • Fipronil
Download as PDF

Product identification

Medicine name:
EFFIPRO 268 MG SPOT-ON SOLUTION FOR LARGE DOGS
Effipro 268 mg/pipetkę Roztwór do nakrapiania
Active substance:
  • Fipronil
Target species:
  • Dog
Route of administration:
  • Cutaneous use

Product details

Active substance and strength:
  • Fipronil
    268.00
    milligram(s)
    /
    1.00
    Pipette
Pharmaceutical form:
  • Spot-on solution
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QP53AX15
Legal status of supply:
  • Veterinary medicinal product not subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Poland
Available in:
  • Poland
Package description:
  • Available only in Polish
  • Available only in Polish
  • Box containing 4 pipettes of 2.68 mL
  • Box containing 6 pipettes of 2.68 mL
  • Box containing 8 pipettes of 2.68 mL
  • Box containing 12 pipettes of 2.68 mL
  • Box containing 24 pipettes of 2.68 mL
  • Box containing 30 pipettes of 2.68 mL
  • Box containing 60 pipettes of 2.68 mL
  • Box containing 90 pipettes of 2.68 mL
  • Box containing 150 pipettes of 2.68 mL
  • Box containing 1 blister pack of 1 pipette of 2.68 mL
  • Box containing 2 blister packs of 1 pipette of 2.68 mL
  • Box containing 3 blister packs of 1 pipette of 2.68 mL
  • Box containing 4 blister packs of 1 pipette of 2.68 mL
  • Box containing 6 blister packs of 1 pipette of 2.68 mL
  • Box containing 8 blister packs of 1 pipette of 2.68 mL
  • Box containing 12 blister packs of 1 pipette of 2.68 mL
  • Box containing 24 blister packs of 1 pipette of 2.68 mL
  • Box containing 30 blister packs of 1 pipette of 2.68 mL
  • Box containing 60 blister packs of 1 pipette of 2.68 mL
  • Box containing 90 blister packs of 1 pipette of 2.68 mL
  • Box containing 150 blister packs of 1 pipette of 2.68 mL
  • Box containing 1 pipette of 2.68 mL

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Hybrid application (Article 13(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Virbac
Marketing authorisation date:
Manufacturing sites for batch release:
  • Virbac
Responsible authority:
  • Office For Registration Of Medicinal Products Medical Devices And Biocidal Products
Authorisation number:
  • 1904
Date of authorisation status change:
Reference member state:
  • France
Procedure number:
  • FR/V/0377/003
Concerned member states:
  • Austria
  • Belgium
  • Bulgaria
  • Cyprus
  • Czechia
  • Denmark
  • Estonia
  • Finland
  • Germany
  • Greece
  • Hungary
  • Ireland
  • Italy
  • Latvia
  • Lithuania
  • Luxembourg
  • Netherlands
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Slovenia
  • Spain
  • Sweden
  • United Kingdom (Northern Ireland)

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Polish (PDF)
Published on: 4/02/2022
Download

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Polish (PDF)
Published on: 4/02/2022
Download

Labelling

This document does not exist in this language (English). You can find it in another language below.
Polish (PDF)
Published on: 4/02/2022
Download